Cost of Revenue of Novo Integrated Sciences, Inc. from 31 May 2016 to 31 Aug 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Novo Integrated Sciences, Inc. quarterly and annual Cost of Revenue in USD history and change rate from 31 May 2016 to 31 Aug 2024.
  • Novo Integrated Sciences, Inc. Cost of Revenue for the quarter ending 31 Aug 2024 was $1,503,189, a 37% decline year-over-year.
  • Novo Integrated Sciences, Inc. Cost of Revenue for the twelve months ending 31 Aug 2024 was $7,551,853, a 0.88% decline year-over-year.
  • Novo Integrated Sciences, Inc. annual Cost of Revenue for 2024 was $7,551,853, a 0.88% decline from 2023.
  • Novo Integrated Sciences, Inc. annual Cost of Revenue for 2023 was $7,619,304, a 9.8% increase from 2022.
  • Novo Integrated Sciences, Inc. annual Cost of Revenue for 2022 was $6,938,699, a 27% increase from 2021.
Source SEC data
View on sec.gov
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Change (%)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Change (%)

Novo Integrated Sciences, Inc. Quarterly Cost of Revenue (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $7,551,853 $1,503,189 -$871,923 -37% 01 Jun 2024 31 Aug 2024 10-K 18 Dec 2024 2024 FY
Q2 2024 $8,423,776 $2,254,958 +$276,119 +14% 01 Mar 2024 31 May 2024 10-Q 19 Jul 2024 2024 Q3
Q1 2024 $8,147,657 $1,846,506 +$260,900 +16% 01 Dec 2023 29 Feb 2024 10-Q 15 Apr 2024 2024 Q2
Q4 2023 $7,886,757 $1,947,200 +$267,453 +16% 01 Sep 2023 30 Nov 2023 10-Q 22 Jan 2024 2024 Q1
Q3 2023 $7,619,304 $2,375,112 +$10,427,744 01 Jun 2023 31 Aug 2023 10-K 18 Dec 2024 2024 FY
Q2 2023 $2,808,440 $1,978,839 -$9,464,162 -83% 01 Mar 2023 31 May 2023 10-Q 19 Jul 2024 2024 Q3
Q1 2023 $6,655,722 $1,585,606 -$67,263 -4.1% 01 Dec 2022 28 Feb 2023 10-Q 15 Apr 2024 2024 Q2
Q4 2022 $6,722,985 $1,679,747 -$215,714 -11% 01 Sep 2022 30 Nov 2022 10-Q 22 Jan 2024 2024 Q1
Q3 2022 $6,938,699 $8,052,632 -$9,765,869 -570% 01 Jun 2022 31 Aug 2022 10-K 14 Dec 2023 2023 FY
Q2 2022 $16,704,568 $11,443,001 +$10,342,485 +940% 01 Mar 2022 31 May 2022 10-Q 17 Jul 2023 2023 Q3
Q1 2022 $6,362,083 $1,652,869 +$328,421 +25% 01 Dec 2021 28 Feb 2022 10-Q 26 May 2023 2023 Q2
Q4 2021 $6,033,662 $1,895,461 +$551,405 +41% 01 Sep 2021 30 Nov 2021 10-Q 24 May 2023 2023 Q1
Q3 2021 $5,482,257 $1,713,237 +$689,819 +67% 01 Jun 2021 31 Aug 2021 10-K 03 Apr 2023 2022 FY
Q2 2021 $4,792,438 $1,100,516 +$540,540 +97% 01 Mar 2021 31 May 2021 10-Q 14 Jul 2022 2022 Q3
Q1 2021 $4,251,898 $1,324,448 -$261,412 -16% 01 Dec 2020 28 Feb 2021 10-Q 13 Apr 2022 2022 Q2
Q4 2020 $4,513,310 $1,344,056 -$288,885 -18% 01 Sep 2020 30 Nov 2020 10-Q 18 Jan 2022 2022 Q1
Q3 2020 $4,802,195 $1,023,418 -$573,275 -36% 01 Jun 2020 31 Aug 2020 10-K 14 Dec 2021 2021 FY
Q2 2020 $5,375,470 $559,976 -$996,889 -64% 01 Mar 2020 31 May 2020 10-Q 14 Jul 2021 2021 Q3
Q1 2020 $6,372,359 $1,585,860 +$265,120 +20% 01 Dec 2019 29 Feb 2020 10-Q 14 Apr 2021 2021 Q2
Q4 2019 $6,107,239 $1,632,941 +$204,858 +14% 01 Sep 2019 30 Nov 2019 10-Q 13 Jan 2021 2021 Q1
Q3 2019 $5,902,381 $1,596,693 +$258,605 +19% 01 Jun 2019 31 Aug 2019 10-K 09 Dec 2020 2020 FY
Q2 2019 $5,643,776 $1,556,865 +$138,866 +9.8% 01 Mar 2019 31 May 2019 10-Q 14 Jul 2020 2020 Q3
Q1 2019 $5,504,910 $1,320,740 +$13,144 +1% 01 Dec 2018 28 Feb 2019 10-Q 20 Apr 2020 2020 Q2
Q4 2018 $5,491,766 $1,428,083 +$20,390 +1.4% 01 Sep 2018 30 Nov 2018 10-Q 13 Jan 2020 2020 Q1
Q3 2018 $5,471,376 $1,338,088 +$83,305 +6.6% 01 Jun 2018 31 Aug 2018 10-K 20 Nov 2019 2019 FY
Q2 2018 $5,388,071 $1,417,999 +$41,088 +3% 01 Mar 2018 31 May 2018 10-Q 11 Jul 2019 2019 Q3
Q1 2018 $5,346,983 $1,307,596 +$117,688 +9.9% 01 Dec 2017 28 Feb 2018 10-Q 11 Apr 2019 2019 Q2
Q4 2017 $5,229,295 $1,407,693 +$243,580 +21% 01 Sep 2017 30 Nov 2017 10-Q 11 Jan 2019 2019 Q1
Q3 2017 $4,985,715 $1,254,783 01 Jun 2017 31 Aug 2017 10-K 06 Nov 2018 2018 FY
Q2 2017 $1,376,911 +$167,082 +14% 01 Mar 2017 31 May 2017 10-Q 11 Jul 2018 2018 Q3
Q1 2017 $1,189,908 01 Dec 2016 28 Feb 2017 10-Q 12 Apr 2018 2018 Q2
Q4 2016 $1,164,113 01 Sep 2016 30 Nov 2016 10-Q 12 Jan 2018 2018 Q1
Q2 2016 $1,209,829 01 Mar 2016 31 May 2016 10-Q 24 Jul 2017 2017 Q3

Novo Integrated Sciences, Inc. Annual Cost of Revenue (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $7,551,853 -$67,451 -0.88% 01 Sep 2023 31 Aug 2024 10-K 18 Dec 2024 2024 FY
2023 $7,619,304 +$680,605 +9.8% 01 Sep 2022 31 Aug 2023 10-K 18 Dec 2024 2024 FY
2022 $6,938,699 +$1,456,442 +27% 01 Sep 2021 31 Aug 2022 10-K 14 Dec 2023 2023 FY
2021 $5,482,257 +$680,062 +14% 01 Sep 2020 31 Aug 2021 10-K 03 Apr 2023 2022 FY
2020 $4,802,195 -$1,100,186 -19% 01 Sep 2019 31 Aug 2020 10-K 14 Dec 2021 2021 FY
2019 $5,902,381 +$431,005 +7.9% 01 Sep 2018 31 Aug 2019 10-K 09 Dec 2020 2020 FY
2018 $5,471,376 +$485,661 +9.7% 01 Sep 2017 31 Aug 2018 10-K 20 Nov 2019 2019 FY
2017 $4,985,715 +$315,100 +6.7% 01 Sep 2016 31 Aug 2017 10-K 06 Nov 2018 2018 FY
2016 $4,670,615 01 Sep 2015 31 Aug 2016 10-K 08 Dec 2017 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.